Intravitreal Bevacizumab for Inflammatory Neovascular Membranes
- Sponsor
- Asociación para Evitar la Ceguera en México
- Study ID
- NCT00407121
- Phase
- PHASE3
- Status
- Withdrawn
Conditions
- Multifocal Choroiditis
- Serpiginous Choroiditis
- Vogt Koyanagi Harada Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 25 Years - 60 Years
- Healthy Volunteers
- Not accepted
Interventions
- Bevacizumab — DRUG
- Intravitreal Injection of Bevacizumab — PROCEDURE
Study Details
Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.
Key Dates
- First listed
- Dec 4, 2006
- Start date
- Dec 31, 2006
- Status verified
- May 2024
- Primary completion
- Dec 31, 2006
- Completion
- Dec 31, 2006
Study Design
- Enrollment
- 0 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
Best corrected visual acuity